NCT01355393View on ClinicalTrials.gov

Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

November 30, 2013

Conditions
HER2-positive Breast CancerMale Breast CancerRecurrent Breast CancerStage II Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerStage IV Breast Cancer
Interventions
BIOLOGICAL

HER-2/neu peptide vaccine

Given ID

BIOLOGICAL

sargramostim

Given ID

DRUG

rintatolimod

Given ID

Trial Locations (1)

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Washington

OTHER

NCT01355393 - Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer | Biotech Hunter | Biotech Hunter